Jenburkt Pharmaceuticals Share Price Today | Stock Price & Jenburkt Pharmaceuticals Share Screener
As of October 5, 2026, the live Jenburkt Pharmaceuticals share price (NSE: JENBURPH) is ₹900.40 on NSE and ₹900.00 on BSE, down 1.62% from the previous close, with shares trading between ₹897.25 and ₹934.00 in today's trading session, and a 52-week range of ₹900.40–₹1,054.40. Check Jenburkt Pharmaceuticals 52-week for the annual price range and momentum. Use the Jenburkt Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Jenburkt Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹178 and net income of ₹33, with EBITDA of ₹47, an operating margin of 22.0% and a profit margin of 18.5%.
Jenburkt Pharmaceuticals Share Price Chart
Track the current stock price of Jenburkt Pharmaceuticals with an interactive chart. Analyse JENBURPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Jenburkt Pharmaceuticals stock quote in one place.
The quote of ₹900.40 sits between the 52-week low of ₹900.40 and the 52-week high of ₹1,054.40, and the latest session moved -1.62% from the previous close.
Jenburkt Pharmaceuticals Company Profile - Fundamental Screener
Screen Jenburkt Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JENBURPH shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE354A01013.
Company Details
Classification
Identifiers and Leadership
Jenburkt Pharmaceuticals Balance Sheet Screener
Screen JENBURPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹226, up from ₹196 in 2025.
Latest statistics put total assets at ₹226 and shareholder funds at ₹197, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 226 | 196 | 165 | 142 | 143 | 121 | 104 | 103 | 78 | 76 |
| Current Assets | 95 | 57 | 110 | 81 | 76 | 80 | 90 | 90 | 66 | 64 |
| Fixed Assets | 20 | 15 | 10 | 10 | 11 | 11 | 12 | 10 | 10 | 11 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 6 | 6 | 4 | 4 | 4 | 5 | 5 | 3 | 3 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 197 | 172 | 145 | 122 | 117 | 99 | 80 | 78 | 61 | 54 |
| Share Capital | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 193 | 167 | 141 | 118 | 113 | 94 | 75 | 73 | 57 | 50 |
Jenburkt Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Jenburkt Pharmaceuticals income statement and profit fundamentals. Analyze JENBURPH quarterly results. Jenburkt Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹178 and net profit was ₹33, equal to earnings per unit of ₹74.40, at an operating margin of 22%.
In that period expenses were ₹132, interest cost ₹0 and tax ₹12. The next period listed, 2026-March, shows revenue of ₹179 and net profit of ₹35.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 178 | 179 | 158 | 147 | 142 | 129 | 114 | 123 | 126 | 118 | 106 | 96 | 87 |
| Expenses | 132 | 125 | 111 | 109 | 106 | 97 | 90 | 99 | 98 | 91 | 84 | 77 | 70 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 47 | 54 | 47 | 38 | 36 | 32 | 24 | 24 | 28 | 27 | 23 | 19 | 17 |
| Operating Profit % | 22.00% | 26.00% | 27.00% | 23.00% | 22.00% | 22.00% | 18.00% | 17.00% | 20.00% | 21.00% | 19.00% | 18.00% | 18.00% |
| Depreciation | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 3 |
| Interest | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 43 | 47 | 44 | 35 | 33 | 30 | 22 | 21 | 27 | 25 | 21 | 17 | 14 |
| Tax | 12 | 12 | 12 | 9 | 8 | 8 | 5 | 6 | 7 | 8 | 7 | 6 | 5 |
| Net Profit | 33 | 35 | 32 | 26 | 25 | 22 | 17 | 15 | 20 | 17 | 14 | 11 | 10 |
| EPS | 74.40 | 78.71 | 72.65 | 58.86 | 53.90 | 48.58 | 35.96 | 32.40 | 43.14 | 37.50 | 29.05 | 23.18 | 20.75 |
Jenburkt Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen JENBURPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹27, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹20 and financing activities used ₹9.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 27 | 28 | 8 | 17 | 9 | 20 | 15 | 13 | 16 | 10 |
| Investing Activities | -20 | -17 | -1 | 3 | -1 | -19 | -3 | -11 | 1 | -10 |
Financing and Net Cash | ||||||||||
| Financing Activities | -9 | -8 | -7 | -21 | -6 | -1 | -11 | -2 | -18 | 1 |
| Net Cash Flow | -2 | 3 | 1 | -1 | 3 | 0 | 1 | 0 | -1 | 1 |
Jenburkt Pharmaceuticals Shareholding Pattern Screener
See Jenburkt Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Jenburkt Pharmaceuticals promoter holding and ownership changes for JENBURPH on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 46.64%, foreign institutions 0.00%, domestic institutions 0.12% and the public 41.03%, spread across 6,999 shareholders.
The shareholder count was 6,999 in 2026-Mar, compared with 7,103 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 46.64% | 46.62% | 46.68% | 46.67% | 46.66% | 46.65% | 47.23% | 46.71% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 41.03% | 41.05% | 43.55% | 43.32% | 43.26% | 43.13% | 42.65% | 43.39% |
| Other Holding | 12.21% | 12.21% | 9.66% | 9.89% | 9.97% | 10.10% | 10.11% | 9.90% |
| Shareholder Count | 6,999 | 7,103 | 6,987 | 6,712 | 6,855 | 7,163 | 6,316 | 6,419 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Jenburkt Pharmaceuticals. Jenburkt Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹20.70 per unit for 2026-March, a yield of 2.26%, compared with ₹18.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹20.70, ₹18.00 and ₹15.30 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹20.70 | 2.26% |
| 2025-March | ₹18.00 | 1.88% |
| 2024-March | ₹15.30 | 1.51% |
| 2023-March | ₹14.40 | 2.09% |
| 2022-March | ₹12.00 | 1.82% |
| 2021-March | ₹10.20 | 1.80% |
| 2020-March | ₹8.10 | 2.03% |
| 2019-March | ₹10.20 | 3.21% |
| 2018-March | ₹9.00 | 1.78% |
| 2017-March | ₹8.10 | 1.32% |
Jenburkt Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Jenburkt Pharmaceuticals stock. Check JENBURPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Jenburkt Pharmaceuticals Market Events Screener - Corporate Actions
Get Jenburkt Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Jenburkt Pharmaceuticals stock events that may affect JENBURPH share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 4, 2026, with a record date of September 4, 2026.
It is followed by Dividend dated August 28, 2026 and Quarterly Result Announcement dated August 6, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-04 | 2026-09-04 | Annual General Meeting | NA | -0.21% |
| 2026-08-28 | 2026-08-28 | Dividend | ₹ 20.70 /share | -0.90% |
| 2026-08-06 | 2026-08-06 | Quarterly Result Announcement | NA | 9.31% |
| 2026-05-05 | 2026-05-05 | Quarterly Result Announcement | NA | -1.25% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | -2.87% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | 0.91% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -9.73% |
| 2025-07-18 | 2025-07-18 | Annual General Meeting | NA | 18.69% |
| 2025-07-11 | 2025-07-11 | Dividend | ₹ 18.00 /share | 25.87% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 9.69% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -6.60% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | 7.15% |
| 2024-07-30 | 2024-07-30 | Annual General Meeting | NA | 16.63% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 15.30 /share | 8.04% |
| 2023-07-19 | 2023-07-20 | Dividend | ₹ 14.40 /share | 3.72% |
Jenburkt Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen JENBURPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Jenburkt Pharmaceuticals Company Announcements - News & Reports Screener
Screen JENBURPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 22, 2026.
The next most recent announcements are dated September 22, 2026 and September 18, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-22 | Intimation Regarding Admission Of Equity Shares Of The Company Under Permitted To Trade Category On National Stock Exchange Of India Limited. | - |
| 2026-09-22 | Closure of Trading Window | - |
| 2026-09-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-09-04 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-04 | Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday 04Th September 2026. | - |
| 2026-09-04 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2026. | - |
| 2026-08-06 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 06Th August 2026. | - |
| 2026-08-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-03 | Notice Of The 41St Annual General Meeting Of The Company Schedule To Be Held On Friday 04Th September 2026 Through VC/OAVM. | - |
| 2026-08-03 | Reg. 34 (1) Annual Report. | - |
| 2026-07-29 | Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2026. | - |
| 2026-07-13 | Announcement under Regulation 30 (LODR)-Change in Registered Office Address | - |
| 2026-07-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-18 | Closure of Trading Window | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-07 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹900.40, within a 52-week range of ₹900.40 to ₹1,054.40. The P/E ratio is 12.34 and the P/B ratio is 2.06, with earnings per unit of ₹78.71. Market capitalisation stands at ₹403.93 Cr and the dividend yield is 2.25%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.